Cookie Policy - To find out more about cookies on this website, see our privacy policy

Cookie Policy

We Help Companies Find New Sales Opportunities

We Help Companies Find New Sales Opportunities


Skyepharma is to sell its injectable drugs business to Blue Acquisition for up to £42m, in order to focus on its Flutiform asthma treatment, and has also announced plans to raise £15m in a share placing.

Skyepharma is planning to relocate its London headquarters from Piccadilly to a less expensive area, in order to cut costs.

Skyepharma is to raise £35m in a rights issue to fund the development of its Flutiform asthma drug.

Skyepharma has invested £2.5m in Micap of Newton-le-Willows, in order to investigate the pharmaceutical applications of Micap's micro-encapsulation technology.

Skyepharma is to raise £60m through a convertible bond in order to fund the development of its own drugs, having decided to change its strategy away from developing products for other companies.

Skyepharma is forming a joint venture with PA Consulting to develop a new asthma inhaler.

Skyepharma is acquiring Hyal Pharmaceutical Corporation of Canada for £3.8m.

Skyepharma plans to raise £140m on the market to acquire Jago Holdings, the Swiss drug delivery concern.